Cargando…
A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281320/ https://www.ncbi.nlm.nih.gov/pubmed/32408510 http://dx.doi.org/10.3390/cancers12051209 |
_version_ | 1783543895872765952 |
---|---|
author | Okuma, Satoe Matsuda, Yuhei Nariai, Yoshiki Karino, Masaaki Suzuki, Ritsuro Kanno, Takahiro |
author_facet | Okuma, Satoe Matsuda, Yuhei Nariai, Yoshiki Karino, Masaaki Suzuki, Ritsuro Kanno, Takahiro |
author_sort | Okuma, Satoe |
collection | PubMed |
description | This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2–52 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86–170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54–136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20–161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers. |
format | Online Article Text |
id | pubmed-7281320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72813202020-06-19 A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers Okuma, Satoe Matsuda, Yuhei Nariai, Yoshiki Karino, Masaaki Suzuki, Ritsuro Kanno, Takahiro Cancers (Basel) Article This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2–52 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86–170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54–136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20–161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers. MDPI 2020-05-12 /pmc/articles/PMC7281320/ /pubmed/32408510 http://dx.doi.org/10.3390/cancers12051209 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Okuma, Satoe Matsuda, Yuhei Nariai, Yoshiki Karino, Masaaki Suzuki, Ritsuro Kanno, Takahiro A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers |
title | A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers |
title_full | A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers |
title_fullStr | A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers |
title_full_unstemmed | A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers |
title_short | A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers |
title_sort | retrospective observational study of risk factors for denosumab-related osteonecrosis of the jaw in patients with bone metastases from solid cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281320/ https://www.ncbi.nlm.nih.gov/pubmed/32408510 http://dx.doi.org/10.3390/cancers12051209 |
work_keys_str_mv | AT okumasatoe aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT matsudayuhei aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT nariaiyoshiki aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT karinomasaaki aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT suzukiritsuro aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT kannotakahiro aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT okumasatoe retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT matsudayuhei retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT nariaiyoshiki retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT karinomasaaki retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT suzukiritsuro retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers AT kannotakahiro retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers |